A5051637354- Ovarian cancer diagnosis and treatment
- PI3K/AKT/mTOR signaling in cancer
- Cancer, Lipids, and Metabolism
- CRISPR and Genetic Engineering
- Plant Virus Research Studies
- Intellectual Property Rights and Media
- HER2/EGFR in Cancer Research
- DNA Repair Mechanisms
- BRCA gene mutations in cancer
The Maria Sklodowska-Curie National Research Institute of Oncology
2016-2021
Centrum Onkologii
2016
EMSY, a BRCA2-associated protein, is amplified and overexpressed in various sporadic cancers. This the first study assessing clinical impact of its expression polymorphisms on ovarian cancer (OvCa) outcome context chemotherapy regimen used. In 134 frozen OvCa samples, we assessed EMSY mRNA with Reverse Transcription-quantitative PCR, also investigated gene sequence using SSCP and/or PCR-sequencing. Clinical relevance changes DNA was evaluated two subgroups treated either taxane/platinum (TP,...
<h3>Introduction/Background*</h3> The PI3K/AKT signaling pathway is activated in a wide spectrum of human cancers. <i>INPP4B</i> tumor suppressor gene encoding lipid phosphatase type II - negative regulator the PI3K signaling. We aimed to determine mechanisms inactivation ovarian cancer. <h3>Methodology</h3> Among 194 cancers studied, there were 126 serous, 23 endometrioid, 18 clear cell, 10 mucinous and 17 other carcinomas. mutations analyzed 52 carcinomas using Sanger sequencing method....
Wstęp. Rak piersi jest najczęstszym nowotworem u kobiet w Polsce. Nadmierna ekspresja białka HER2 lub amplifikacja genu związana ze złym rokowaniem i stanowi wskazanie do zastosowania terapii anty-HER2. W przypadkach wątpliwych rozstrzygającym badaniem ocena FISH, wskazująca status amplifikacji według obowiązujących wytycznych ASCO-CAP, które roku 2013 uległy zmianom. Celem pracy było sprawdzenie, czy jaki sposób zmiana zaleceń wpłynęła na rozkład wyników badań FISH tej grupie pacjentów....
<h3>Introduction/Background</h3> The phosphoinositide 3-kinase (PI3K) signaling cascade is one of the most frequently deregulated cascades in human cancers. possibility its inhibiting makes PI3K pathway an attractive target for personalized therapy. We aimed to determine mRNA expression <i>PIK3R1</i>, a gene encoding p85α regulatory subunit PI3K. <h3>Methodology</h3> <i>PIK3R1</i> analysis was carried out 144 ovarian cancers and 5 specimens noncancerous fallopian tube as control group....